Effect of troponin I and coagulation parameters on mortality in COVID-19 patients

Year 2023, , 135 - 139, 31.01.2023

Meral Dag Nilufer Bulut M. Cagatay Taskapan

https://doi.org/10.5472/marumj.1235703

Abstract

Objective: Our aim is to determine the levels of troponin-I and some coagulation markers (D-dimer, fibrinogen and International Normalized Ratio (INR)) in coronavirus disease 2019 (COVID-19) patients and to investigate the effects of these markers on mortality.
Patients and Methods: It is planned as a descriptive, cross-sectional and analytical study. The study was conducted by retrospectively scanning the files of COVID-19 patients who applied to Inonu University Turgut Ozal Medical Center between 01.03.2020 and 31.12.2020. Levels of cardiac troponin I markers and coagulation parameters (D-dimer, fibrinogen and INR) were detected.
Results: The results of a total of 1858 patients were obtained. One thousand, three hundred and twenty-six patients with only troponin I and D-dimer results (Group 1), 606 patients with only troponin I and fibrinogen results (Group 2), and 1308 patients with only troponin I and INR results (Group 3) were included. Troponin I levels were significantly higher in all patients who died. 96.6% of the patients with high D-dimer levels died in Group 1, 85.5% of the patients with high fibrinogen levels died in Group 2 and 77.3 % of the patients with high INR levels died in Group 3.
Conclusion: Measurements of troponin-I and coagulation markers such as D-dimer, fibrinogen and INR can help predict clinical severity and mortality in COVID-19 patients.

Keywords

COVID-19, Troponin I, Coagulation markers, D-dimer, Fibrinogen, International Normalized Ratio.

References

• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323:1239-42. doi: 10.1001/jama.2020.2648.
• Gülbahar M, Gök MZ. Koronavirüs-19'un Kardiyovasküler Sistem Üzerine Etkileri. Turkiye Klinikleri J Nurs Sci 2020; 12 :305-14. doi:10.5336/nurses.2020-75550.
• Gemalmaz H, Gültekin Y, Kural T. Açık kalp cerrahisinde 72 saatlik trimetazidin uygulamasının miyokard iskemisi üzerine etkileri. Kırıkkale Uni Med J 2021; 23:49-58. doi: 10.24938/kutfd.824624.
• Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18:844-7. doi: 10.1111/jth.14768.
• Srivastava S, Garg I, Bansal A, Kumar B. COVID-19 infection and thrombosis. Clinica Chimica Acta 2020; 510:344-6. doi: 10.1016/j.cca.2020.07.046.
• Wang Y, Shu H, Liu H, et al. The peak levels of highly sensitive troponin I predicts in-hospital mortality in COVID-19 patients with cardiac injury: a retrospective study. Eur Heart J Acute Cardiovasc Care 2021; 10: 6-15. doi: 10.1093/ehjacc/zuaa019.
• Xiong TY. Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020; 41:1798-800. doi: 10.1093/eurheartj/ehaa231.
• Li C, Jiang J, Wang F, et al. Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients. J Mol Cell Cardiol 2020; 147:74-87. doi: 10.1016/j.yjmcc.2020.08.008.
• Singh S, Chowdhry M, Chatterjee A, Khan A. Gender-based disparities in COVID-19 patient outcomes: A propensity-matched analysis. medRxiv 2020:2020.04.24.20079046. doi: 10.1101/2020.04.24.20079046.
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584(7821):430-6. doi:10.1038/s41586-020-2521-4.
• Chen TL, Dai Z, Mo P, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: A single-centered, retrospective study. J Gerontol A Biol Sci Med Sci Series A 2020; 75:1788–95, doi: 10.1093/gerona/glaa089.
• Li P, Chen L, Liu Z, et al. Clinical features and short-term outcomes of elderly patients with COVID-19. Int J Infect Dis 2020; 97:245-50. doi: 10.1016/j.ijid.2020.05.107.
• Stefanini GG, Chiarito M, Ferrante G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart 2020; 106:1512-8. doi: 10.1136/heartjnl-2020-317322.
• Qin JJ, Cheng X, Zhou F, et al. Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19. Hypertension 2020; 76:1104-12. doi: 10.1161/HYPERTENSIONAHA.120.15528.
• Leidi A, Rouyer F, Marti C, Reny JL, Grosgurin O. Point of care ultrasonography from the emergency department to the internal medicine ward: current trends and perspectives. Intern Emerg Med 2020; 15: 395-408. doi: 10.1007/s11739-020-02498-7.
• Rath D, Petersen-Uribe Á, Avdiu A, et al. Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection. Clin Res Cardiol 2020; 109:1491-9. doi: 10.1007/s00392-020-01683-0.
• Shi S, Qin M, Shen B, et al. Cardiac injury in patients with corona virus disease 2019. JAMA Cardiol 2020; 5(7):802-10. doi: 10.1001/jamacardio.2020.0950.
• Huang C., Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet 2020; 395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
• Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine 2020; 46:846-8. doi: 10.1007/s00134-020-05991-x.
• Miesbach W, Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clinical Appl Thromb Hemost 2020; 26: 1076029620938149. doi: 10.1177/1076029620938149.
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet 2020; 395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3.
• Terpos E, Ntanasis‐Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID‐19. Am J Hematol 2020; 95: 834-47. doi: 10.1002/ajh.25829.
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323:1061-9. doi: 10.1001/jama.2020.1585.
• Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; 58:1116-20. doi: 10.1515/cclm-2020-0188.
• Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135:2033-40. doi: 10.1182/BLOOD.2020006000.
• Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematol 2020; 7:438-40. doi: 10.1016/S2352-3026(20)30145-9.
• Jin X, Duan Y, Bao T, et al. The values of coagulation function in COVID-19 patients. PLoS One 2020; 15:e0241329. doi: 10.1371/journal.pone.0241329.
• Li J, Long X, Zhu C, et al. A case of COVID-19 pneumonia with cerebral hemorrhage. Thromb Res 2020; 193:22-4. doi: 10.1016/j.thromres.2020.05.050.